search
Back to results

Lucentis to Treat Pigment Epithelial Detachment

Primary Purpose

Pigment Epithelial Detachment

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Ranibizumab
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pigment Epithelial Detachment focused on measuring Age Related Macular Degeneration, Pigment Epithelial Detachment, Intravitreal Detachment, Anti-VEGF

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Predominantly PED type lesions as classified on IVFA and OCT secondary to AMD.
  2. PED under the geometric center of the foveal avascular zone.
  3. Evidence of recent disease progression as suggested by one or more of the following: sub-retinal lipid or cystic macular edema, sub-retinal hemorrhage, vision loss within the last 3 months or documented lesion growth on FA over previous 6 months.
  4. Visual acuity of between 20/40 and 20/800 in the study eye - Equivalent to Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart score of 5 to 75 letters at 2 meters.
  5. Ambulatory Vision in the fellow eye
  6. Willingness and ability to participate and provide written informed consent.

Exclusion Criteria:

  1. Individuals with choroidal neovascularization from causes other than AMD.
  2. Patients physically unable to tolerate intravenous fluorescein angiography
  3. Any intraocular surgery within 2 months in the study eye.
  4. Prior retinal or vitreous surgery including vitrectomy or scleral buckling in the study eye.
  5. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome.
  6. Individuals with physical or mental disabilities that prevent accurate vision testing.
  7. History of treatment of CNVM in the study eyes other than extrafoveal confluent laser photocoagulation.
  8. Prior photodynamic therapy for CNV.
  9. Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past.
  10. Women of childbearing potential who are not on two forms of effective contraception during the trial and for at least 60 days following the last dose of study medication.

Sites / Locations

  • Ivey Eye Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lucentis

Arm Description

All patients receive iL for for first 6 months of study. At 6 months - patients are classified as "responders" or "non-responders". "Responders" receive iL PRN based on OCT,clinical exam etc. "Non-responders" are seen again at 12 months for repeat investigations.

Outcomes

Primary Outcome Measures

To investigate whether iL given monthly for 6 months in patients with Predominantly PED lesions (secondary to AMD) will significantly improve mean visual acuity from baseline on a standardized ETDRS chart.

Secondary Outcome Measures

To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions on lesion growth and activity over the study period.
To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions alone on contrast sensitivity.
To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions on central retinal thickness via Optical Coherence Tomography (OCT).
To evaluate the effect of iL given for up to 12 months in patients with Predominantly PED lesions on lesion growth and activity over the study period.
To evaluate the effect of iL given for up to 12 months in patients with Predominantly PED lesions on central retinal thickness via Optical Coherence Tomography (OCT).

Full Information

First Posted
February 9, 2009
Last Updated
December 7, 2011
Sponsor
Lawson Health Research Institute
Collaborators
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00841581
Brief Title
Lucentis to Treat Pigment Epithelial Detachment
Official Title
Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lawson Health Research Institute
Collaborators
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.
Detailed Description
Background: Exudative Age Related Macular Degeneration (AMD) results in a significant and severe visual loss if left untreated as documented in natural history and observational arms of studies such as the macular photocoagulation study (MPS) and the Tap and VIP study with Visudyne. It is also clear however, that the different lesion types (classified by intravenous fluorescein angiography ((IVFA)) as occult, minimally classic or predominately classic) have both a different natural history and a different response to treatment. The recent introduction of the anti-VEGF agents such as Macugen and Lucentis have significantly advanced our ability to treat AMD as both agents show clear efficacy across all lesion subtypes regardless of lesion composition. A clear absence of literature on clinical outcomes exist however for fibrovascular pigment epithelial detachments (PED). PED represents a form of exudative AMD which clearly behaves in a unique and distinctive manner when compared to the lesion(s) described above. As standard exclusion criteria within most of the major AMD trials, lesion composition of any IVFA subtype is acceptable as long as less then 50% of the lesion is composed of blood or pigment epithelial detachment. This has resulted in a notable absence of clinical literature on the response of predominately PED type lesions to current standard of care anti-VEGF agents. In an effort to address this absence, a prospective evaluation of the response of predominately PED type lesions to Lucentis, the current gold standard therapy is needed. Study design: Thirty two patients will be recruited to participate based on the Inclusion / Exclusion Criteria described in a later paragraph. Patients will receive monthly intravitreal Lucentis injections every 33 days (+/- 4 days) for 6 months. At 6 months, patients will be evaluated based on ETDRS Visual Acuity and OCT to determine response to Lucentis therapy. Patients not experiencing a visual improvement from baseline ETDRS acuity (defined as a net gain from baseline of 10 or more letters) or showing a reduction in the height of the fibrovascular PED lesion on OCT of greater than 30% from baseline OCT will be deemed Lucentis non-responders. These patients will receive no further intravitreal Lucentis injections, but will undergo re-evaluation at 12 months. Patients deemed responders, will continue with an OCT-guided 6 months active treatment period. In these patients, iL will be administered if evidence of visual loss of 1 or more lines (Snellen) from 6-month visit values, evidence of intraretinal or subretinal fluid on OCT, or growth of PED by greater than 50 microns from the 6-month visit OCT values. Non-responders will be evaluated only at the 12-month final visit. Baseline IVFA, OCT, Snellen Visual Acuity, ETDRS refraction and contrast sensitivity will be obtained along with a comprehensive ophthalmological examination. Complete diagnostic assessments including fluorescein angiography, OCT and visual function testing will be repeated at 3, 6 and 12 months after baseline treatment. In addition, patients who will continue on active intravitreal Lucentis therapy beyond 6 months (responders), will undergo monthly OCT examinations (months 6 through 11) and ophthalmic safety examinations in order to determine the need for Lucentis administration. At the final, Month 12 visit, all patients will undergo ophthalmic examination, OCT, ETDRS refraction, Snellen Visual Acuity and contrast sensitivity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pigment Epithelial Detachment
Keywords
Age Related Macular Degeneration, Pigment Epithelial Detachment, Intravitreal Detachment, Anti-VEGF

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lucentis
Arm Type
Experimental
Arm Description
All patients receive iL for for first 6 months of study. At 6 months - patients are classified as "responders" or "non-responders". "Responders" receive iL PRN based on OCT,clinical exam etc. "Non-responders" are seen again at 12 months for repeat investigations.
Intervention Type
Drug
Intervention Name(s)
Ranibizumab
Other Intervention Name(s)
Lucentis, DIN 02296810
Intervention Description
Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
Primary Outcome Measure Information:
Title
To investigate whether iL given monthly for 6 months in patients with Predominantly PED lesions (secondary to AMD) will significantly improve mean visual acuity from baseline on a standardized ETDRS chart.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions on lesion growth and activity over the study period.
Time Frame
6 months
Title
To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions alone on contrast sensitivity.
Time Frame
6 months
Title
To evaluate the effect of iL given monthly for 6 months in patients with Predominantly PED lesions on central retinal thickness via Optical Coherence Tomography (OCT).
Time Frame
6 months
Title
To evaluate the effect of iL given for up to 12 months in patients with Predominantly PED lesions on lesion growth and activity over the study period.
Time Frame
12 months
Title
To evaluate the effect of iL given for up to 12 months in patients with Predominantly PED lesions on central retinal thickness via Optical Coherence Tomography (OCT).
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Predominantly PED type lesions as classified on IVFA and OCT secondary to AMD. PED under the geometric center of the foveal avascular zone. Evidence of recent disease progression as suggested by one or more of the following: sub-retinal lipid or cystic macular edema, sub-retinal hemorrhage, vision loss within the last 3 months or documented lesion growth on FA over previous 6 months. Visual acuity of between 20/40 and 20/800 in the study eye - Equivalent to Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart score of 5 to 75 letters at 2 meters. Ambulatory Vision in the fellow eye Willingness and ability to participate and provide written informed consent. Exclusion Criteria: Individuals with choroidal neovascularization from causes other than AMD. Patients physically unable to tolerate intravenous fluorescein angiography Any intraocular surgery within 2 months in the study eye. Prior retinal or vitreous surgery including vitrectomy or scleral buckling in the study eye. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome. Individuals with physical or mental disabilities that prevent accurate vision testing. History of treatment of CNVM in the study eyes other than extrafoveal confluent laser photocoagulation. Prior photodynamic therapy for CNV. Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past. Women of childbearing potential who are not on two forms of effective contraception during the trial and for at least 60 days following the last dose of study medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas G Sheidow, MD
Organizational Affiliation
Ivey Eye Institute, LOndon, Ontario, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ivey Eye Institute
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4G5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Lucentis to Treat Pigment Epithelial Detachment

We'll reach out to this number within 24 hrs